Compare Norfolk Southern Corporation (NSC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Novo Nordisk A/S — how do they compare? Norfolk Southern Corporation trades at $317.79 (market cap $71.20B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.3× Norfolk Southern Corporation's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Norfolk Southern Corporation for 33 Days and Novo Nordisk A/S for 116 Days on average.
| NSC | NVO | |
|---|---|---|
Market Cap | $71.20B | $165.31B |
Volume | 555,248 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $352.98 | $63.98 |
52-Week Low | $278.19 | $35.29 |
Typical Hold Time | 33 Days | 116 Days |
Enterprise Value | $86.75B | $179.56B |
Dividend Yield | 1.7% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $316.99, up 1.21% with bullish technical indicators and strong institutional support. The company demonstrates solid fundamentals with consistent earnings beats, a 21.02% net income margin, and robust cash flow from operations. Recent news highlights momentum for the proposed Union Pacific merger, with regulatory review advancing and over 500 customer endorsements supporting the combination's potential benefits.
NSC presents a favorable risk-reward profile with analyst consensus target of $361.86 offering 14% upside. Key opportunities include freight share gains from trucking and merger synergies, while risks involve fuel price pressures and regulatory hurdles for the combination. The stock remains well-positioned for long-term growth with dividend stability.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
